Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00191607 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | PHASE3 | COMPLETED | 162 | — | — | Jul 1, 2002 | Nov 1, 2005 | Jan 26, 2007 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | - |
| liposomal doxorubicin | DRUG | - |
Inclusion Criteria: * All patients must have a documented pathologic diagnosis of epithelial ovarian (FIGO Stage I-IV), Fallopian tube or primary peritoneal carcinoma * Patients must have received platinum-based, first-line chemotherapy but no more than one additional prior chemotherapy regimen. Pa...